Although obesity, insulin resistance, and endogenous hyperinsulinemia are not prerequisites for T1D, its treatment involves exogenous subcutaneous insulin administration, leading to supraphysiological insulin concentrations in the systemic circulation [47]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.